Silence Therapeutics (NASDAQ:SLN) Stock Rating Upgraded by Wall Street Zen

Silence Therapeutics (NASDAQ:SLN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other brokerages have also recently issued reports on SLN. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Tuesday, September 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Wednesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of Silence Therapeutics in a report on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $32.60.

Silence Therapeutics Trading Up 2.0%

SLN opened at $6.58 on Friday. The stock’s 50-day moving average price is $5.76 and its 200 day moving average price is $5.46. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $17.84. The firm has a market cap of $196.94 million, a price-to-earnings ratio of -4.87 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $3.28 million. Silence Therapeutics had a negative return on equity of 61.76% and a negative net margin of 254.25%. On average, research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SLN. Jump Financial LLC acquired a new stake in shares of Silence Therapeutics in the 1st quarter worth approximately $74,000. Walleye Capital LLC increased its position in Silence Therapeutics by 274.1% during the 1st quarter. Walleye Capital LLC now owns 136,150 shares of the company’s stock worth $384,000 after purchasing an additional 99,753 shares in the last quarter. GAMMA Investing LLC raised its stake in Silence Therapeutics by 134.1% in the 2nd quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after purchasing an additional 4,773 shares during the last quarter. Evelyn Partners Investment Management Services Ltd lifted its holdings in Silence Therapeutics by 481.3% in the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after purchasing an additional 11,868 shares in the last quarter. Finally, Beacon Pointe Advisors LLC acquired a new stake in shares of Silence Therapeutics during the 2nd quarter worth about $67,000. 98.73% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.